IP Library Granted Patent US 10,725,052
Granted Patent B2
US 10,725,052 · App. 15/447,789 · Granted Jul 28, 2020

Methods and compositions for the detection and diagnosis of renal disease and periodontal disease

Inventors: Mahalakshmi Yerramilli (Falmouth, ME); Giosi Farace (Georgetown, ME); John J. Quinn (Falmouth, ME); Murthy V. S. N. Yerramilli (Falmouth, ME)
Assignee: IDEXX LABORATORIES, INC.
G01N33/6893C07K14/8139C07K16/38G01N2333/8139G01N2800/18G01N2800/347G01N2800/348G01N2800/52
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,725,052
App. No.
15/447,789
Granted
Jul 28, 2020
Kind
B2
Abstract

The disclosure provides compositions and methods for the detection of renal disease and periodontal disease in mammals.

Claims (12)

1. A method for diagnosis and treatment of renal disease in a subject comprising detecting an amount of cystatin B polypeptides, comparing the amount of the cystatin B polypeptides to a control sample or control standard, wherein the cystatin B polypeptides are selected from the group consisting of SEQ ID NOs:2, 3, 5, 6, 7, 11, and 12, diagnosing the subject with renal disease where elevated levels of cystatin B polypeptides compared to the control sample or control standard are present, and treating the subject for acute kidney injury or chronic kidney renal disease, wherein the treating comprises surgery for obstructive nephron/ureteroliths, chemotherapy for renal neoplasia, dietary management, enteric phosphate binders, administration of antiproteinurics, administration of antihypertensives, fluid therapy, management of acidosis, administration of diuretics, dialysis, correction of electrolyte abnormalities, administration of antiemetics, administration of antacids, or administration of recombinant erythropoietin.

2. The method of claim 1 , wherein the sample is obtained from a non-human animal.

3. The method of claim 1 , wherein the sample is blood, serum, plasma or urine.

4. The method of claim 1 , wherein the cystatin B polypeptides are detected by, a competitive immunoassay, a sandwich immunoassay, an enzyme-linked immunosorbent assay (ELISA), a turbidimetric immunoassay, a particle-enhanced turbidimetric immunoassay, a radioimmunoassay (RIA), or a western blot assay.

5. The method of claim 1 , wherein the cystatin B polypeptides are detected by an immunoassay.

6. The method of claim 1 , wherein the cystatin B polypeptides are SEQ ID NO:2.

7. The method of claim 1 , wherein the cystatin B polypeptides are SEQ ID NO:3.

8. The method of claim 1 , wherein the cystatin B polypeptides are SEQ ID NO:5.

9. The method of claim 1 , wherein the cystatin B polypeptides are SEQ ID NO:6.

10. The method of claim 1 , wherein the cystatin B polypeptides are SEQ ID NO:7.

11. The method of claim 1 , wherein the cystatin B polypeptides are SEQ ID NO:11.

12. The method of claim 1 , wherein the cystatin B polypeptides are SEQ ID NO:12.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 15, 2017
From: YERRAMILLI, MAHALAKSHMI; FARACE, GIOSI; QUINN, JOHN J.; YERRAMILLI, MURTHY V.S.N.
To: IDEXX LABORATORIES, INC.
Reel/Frame 041585/0575 →
Continuity (2)
Provisional Application 62302299 · Mar 2, 2016
Related Publication 20170269101A1 · Sep 21, 2017
Cited By (3)
US 12,345,641 US 12,385,927 US 12,631,655